News
Atezolizumab combo in first-line NSCLC misses cost-effectiveness mark
The incremental cost‐effectiveness ratio of ABCP as compared with BCP or with CP – more than $500,000 per QALY – far exceeded the conventional...
News
Gaps in patient-provider survivorship communication persist
Over a recent 5-year period, there was little change in the percentages of patients who reported not having any detailed discussion with providers...
News
Comorbidities drive excess mortality after breast cancer diagnosis in childhood cancer survivors
A retrospective analysis found that, among matched breast cancer patients, childhood cancer survivors had a more than doubling of all-cause...
News
Racial, age disparities confirmed in triple-negative breast cancer
In a cohort of more than a million breast cancer cases, likelihood of having a tumor with the TNBC phenotype was roughly twice as high for black...
News
Vemurafenib has durable activity in NSCLC harboring BRAF V600 mutations
More than a third of patients had a complete or partial response to monotherapy with the oral BRAF(V600E) kinase inhibitor, and median overall...
News
Multigene panel sequencing is moderately cost-effective in NSCLC
Compared with a single-marker approach, a multigene panel approach had an incremental cost-effectiveness ratio of about $148,000 per life-year...
News
EHR default order slashes unnecessary imaging during palliative RT
After implementation of the default order specifying no daily imaging during palliative radiation therapy, patients were 63% less likely to...
News
Specific prednisone regimen safer than others when used with abiraterone for mCR prostate cancer
Prednisone, 5 mg, twice daily, gave the most favorable overall safety profile when with regard to avoiding mineralocorticoid excess and long-term...
News
Liquid biopsy assays found sensitive for NSCLC EGFR mutations
Two liquid biopsy assays performed well at detecting EGFR mutations in plasma-derived cell-free DNA from patients with NSCLC, possibly...
News
Immunotherapy-treated NSCLC: Adverse impact of steroids driven by palliative indications
A new analysis suggests use of steroids for cancer-related palliation in patients with poor prognosis largely explains their association with...
News
Niraparib-pembrolizumab combo finds niche in breast, ovarian cancers
The combination had good antitumor activity, as well as good safety and tolerability, in patients with advanced TNBC or ovarian carcinoma who were...
News
Neoadjuvant-adjuvant erlotinib shows promise in locally advanced NSCLC
The EMERGING trial failed to meet its primary endpoint of higher OR but did meet the secondary endpoint of longer PFS.
News
Study raises questions about PPS exemption for cancer centers
Hospitals affiliated with PPS-exempt cancer centers and hospitals affiliated with NCI cancer centers were similar on most metrics.
News
Low-dose CT lung cancer screening nets payoff in community setting too
A survey of 165 lung cancer screening centers suggests low-dose CT screening is being effectively implemented in community practices, replicating...
News
Syncope during pregnancy increases risk for poor outcomes
Syncope during pregnancy is not as benign as once thought, carrying higher risks of preterm birth, congenital anomalies, and postpartum cardiac...